316 related articles for article (PubMed ID: 25716885)
21. Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation.
Hilgendorf I; Wolff D; Junghanss C; Kahl C; Leithaeuser M; Steiner B; Casper J; Freund M
Ann Hematol; 2008 Dec; 87(12):1009-12. PubMed ID: 18704421
[TBL] [Abstract][Full Text] [Related]
22. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
Cancer; 2002 Aug; 95(3):576-80. PubMed ID: 12209750
[TBL] [Abstract][Full Text] [Related]
23. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
24. Safety and tolerability of intrathecal liposomal cytarabine as central nervous system prophylaxis in patients with acute lymphoblastic leukemia.
Valentin A; Troppan K; Pfeilstöcker M; Nösslinger T; Linkesch W; Neumeister P
Leuk Lymphoma; 2014 Aug; 55(8):1739-42. PubMed ID: 24138308
[TBL] [Abstract][Full Text] [Related]
25. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma.
Gregory G; Arumugaswamy A; Leung T; Chan KL; Abikhair M; Tam C; Bajel A; Cher L; Grigg A; Ritchie D; Opat S
Neuro Oncol; 2013 Aug; 15(8):1068-73. PubMed ID: 23502429
[TBL] [Abstract][Full Text] [Related]
26. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Ferreri AJ; Reni M; Foppoli M; Martelli M; Pangalis GA; Frezzato M; Cabras MG; Fabbri A; Corazzelli G; Ilariucci F; Rossi G; Soffietti R; Stelitano C; Vallisa D; Zaja F; Zoppegno L; Aondio GM; Avvisati G; Balzarotti M; Brandes AA; Fajardo J; Gomez H; Guarini A; Pinotti G; Rigacci L; Uhlmann C; Picozzi P; Vezzulli P; Ponzoni M; Zucca E; Caligaris-Cappio F; Cavalli F;
Lancet; 2009 Oct; 374(9700):1512-20. PubMed ID: 19767089
[TBL] [Abstract][Full Text] [Related]
27. Liposomal cytarabine for central nervous system embryonal tumors in children and young adults.
Partap S; Murphy PA; Vogel H; Barnes PD; Edwards MS; Fisher PG
J Neurooncol; 2011 Jul; 103(3):561-6. PubMed ID: 20859651
[TBL] [Abstract][Full Text] [Related]
28. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP
Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
Hoang-Xuan K; Taillandier L; Chinot O; Soubeyran P; Bogdhan U; Hildebrand J; Frenay M; De Beule N; Delattre JY; Baron B;
J Clin Oncol; 2003 Jul; 21(14):2726-31. PubMed ID: 12860951
[TBL] [Abstract][Full Text] [Related]
30. Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: a retrospective cohort study.
Fusco JP; Castañón E; Carranza OE; Zubiri L; Martín P; Espinós J; Rodríguez J; Santisteban M; Aramendía JM; Gil-Bazo I
J Neurooncol; 2013 Dec; 115(3):429-35. PubMed ID: 24037499
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.
Wight JC; Yue M; Keane C; Johnston A; Linton K; Chin C; Wai SH; Talaulikar D; Gasiorowski R; Cheah CY; Gregory GP; Dickinson M; Minson A; Coombes C; Ku M; Lam S; Hawkes EA
Br J Haematol; 2019 Oct; 187(2):174-184. PubMed ID: 31236941
[TBL] [Abstract][Full Text] [Related]
32. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis.
Benesch M; Sovinz P; Krammer B; Lackner H; Mann G; Schwinger W; Gadner H; Urban C
J Pediatr Hematol Oncol; 2007 Apr; 29(4):222-6. PubMed ID: 17414563
[TBL] [Abstract][Full Text] [Related]
33. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study.
Perry C; Ben Barouch S; Goldschmidt N; Sarid N; Herishanu Y; Shvidel L; Bairey O; Lavi N; Horowitz N; Avigdor A; Lebel E; Sofer O; Ram R; Avivi I
Am J Hematol; 2019 Sep; 94(9):992-1001. PubMed ID: 31211434
[TBL] [Abstract][Full Text] [Related]
34. Prophylactic intrathecal chemotherapy in primary CNS lymphoma.
Sierra Del Rio M; Ricard D; Houillier C; Navarro S; Gonzalez-Aguilar A; Idbaih A; Kaloshi G; Elhallani S; Omuro A; Choquet S; Soussain C; Hoang-Xuan K
J Neurooncol; 2012 Jan; 106(1):143-6. PubMed ID: 21739169
[TBL] [Abstract][Full Text] [Related]
35. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
[TBL] [Abstract][Full Text] [Related]
36. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
Aichberger KJ; Herndlhofer S; Agis H; Sperr WR; Esterbauer H; Rabitsch W; Knöbl P; Haas OA; Thalhammer R; Schwarzinger I; Sillaber C; Jäger U; Valent P
Eur J Clin Invest; 2007 Oct; 37(10):808-13. PubMed ID: 17727673
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma.
Garcia-Marco JA; Panizo C; Garcia ES; Deben G; Alvarez-Larran A; Barca EG; Sancho JM; Penarrubia MJ; Garcia-Cerecedo T; Garcia Vela JA
Cancer; 2009 May; 115(9):1892-8. PubMed ID: 19235254
[TBL] [Abstract][Full Text] [Related]
38. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
39. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.
El-Galaly TC; Cheah CY; Bendtsen MD; Nowakowski GS; Kansara R; Savage KJ; Connors JM; Sehn LH; Goldschmidt N; Shaulov A; Farooq U; Link BK; Ferreri AJM; Calimeri T; Cecchetti C; Dann EJ; Thompson CA; Inbar T; Maurer MJ; Gade IL; Juul MB; Hansen JW; Holmberg S; Larsen TS; Cordua S; Mikhaeel NG; Hutchings M; Seymour JF; Clausen MR; Smith D; Opat S; Gilbertson M; Thanarajasingam G; Villa D
Eur J Cancer; 2018 Apr; 93():57-68. PubMed ID: 29477102
[TBL] [Abstract][Full Text] [Related]
40. [Liposomal cytarabine for the treatment of leptomeningeal dissemination of central nervous system tumours in children and adolescents].
Moreno L; García Ariza MA; Cruz O; Calvo C; Fuster JL; Salinas JA; Moscardo C; Portugal R; Merino JM; Madero L
An Pediatr (Barc); 2016 Nov; 85(5):274.e1-274.e8. PubMed ID: 27086069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
